Mannose 6-phosphonate labelling: A key for processing the therapeutic enzyme in Pompe disease.

Godefroy A, Daurat M, Da Silva A,  Basile I, El Cheikh K,  Caillaud C, Sacconi S, Schoser B, Charbonne HV, Gary-Bobo M,  Morere A,  Garcia M and Maynadier M.
J Cell Mol Med 2019;23:6499-6503.

Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid alpha-glucosidase.

Basile I, Da Silva A, El Cheikh K,  Godefroy A, Daurat M, Harmois A, Perez M, Caillaud C, Charbonne HV,  Pau B, Gary-Bobo M,  Morere A,  Garcia M and Maynadier M.
J Control Release 2018,269:15-23.

Design of potent mannose 6-phosphate analogues for the functionalization of lysosomal enzymes to improve the treatment of Pompe disease.

El Cheikh K, Basile I, Da Silva A, Bernon C, Cérutti P, Salgues F, Perez M, Maynadier M, Gary-Bobo M, Caillaud C, Cérutti M,  Garcia M and Morere A.
Angew Chem Int Ed Engl 2016,55:14774-14777.


Why anticancer nanomedicine needs sugars?

Bouffard E, El Cheikh K, Gallud A, Da Silva A, Maynadier M, Basile I, Gary-Bobo M, Morere A, Garcia M.
Curr Med Chem 2015 ;22(26):3014-24.


Identification of MRC2 and CD209 receptors as targets for photodynamic therapy of retinoblastoma using mesoporous silica nanoparticles.

Gallud A, Warther D, Maynadier M, Sefta M, Poyer F, Thomas C, Rouxel C, Mongin O, Blanchard-Desce M, Morère A, Raehm L, Maillard P, Durand JO, Garcia M, Gary-Bobo M.
RSC Adv 2015, 5, 75167-72.


Mannose-6-phosphate receptor: a target for theranostics of prostate cancer

Vaillant O, El Cheikh K, Warther D, Brevet D, Maynadier M, Bouffard E, Salgues F, Jeanjean A, Puche P, Mazerolles C, Maillard P, Mongin O, Blanchard-Desce M, Raehm L, Rébillard X, Durand JO, Gary-Bobo M, Morère A and Garcia M.
Angew Chem Int Ed Engl. 2015 ;54(20):5952-6.


Targeting multiplicity: the key for anti-cancer nanoparticles.

Gary-Bobo M, Vaillant O, Maynadier M, Basile I, Gallud A, El Cheikh K, Bouffard E, Morère A, Rébillard X, Puche P, Nirdé P, Garcia M.
Curr Med Chem. 2013, 20(15):1946-55.